AbbVie Reports Full-Year 2015 and Fourth-Quarter Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/27/2026
- Wall Street stocks end tad lower after hot inflation data ahead of Nvidia earnings
- Nvidia forecasts quarterly revenue above estimates, shares rise
- Oil settles down after choppy session as investors weigh Hormuz talks
- Meta to pay up to $16.68 billion in mass social media settlement
- Anthropic agrees to $45bn cloud computing deal with Nscale - report
- Nutanix (NTNX) Tops Q4 EPS by 11c, Beats in Revenue; Offers Q1 Revenue Guidance
- Boston Scientific discloses cybersecurity incident causing global disruption
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
- FDA approves Revolution Medicines pancreatic cancer drug Rasonque
- NVIDIA (NVDA) Tops Q2 EPS by 14c, Offers Guidance
AbbVie (ABBV) Tops Q4 EPS by 1c
January 29, 2016 7:48 AM ESTAbbVie (NYSE: ABBV) reported Q4 EPS of $1.13, $0.01 better than the analyst estimate of $1.12. Revenue for the quarter came in at $6.36 billion versus the consensus estimate of $6.37 billion.
"AbbVie delivered strong performance in 2015, exceeding original sales, margin expansion, and earnings projections for the year," said Richard A. Gonzalez, chairman and chief executive officer, AbbVie. "We achieved significant growth in 2015, and expect to continue building on that momentum in 2016 with another year of strong performance."
Fourth quarter highlights:
Worldwide adjusted net revenues were $6.360 billion in the fourth-quarter, up 18.4 percent. On an operational basis, adjusted net... More